bioporto
DIAGNOSTICS

2023-Q3 Financial Results & Business Update

Empowering Early Detection of Kidney Injury

November 1, 2023

Forward-Looking Statements

References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the "Company" or "BioPorto"), and any further information that may be made available in connection with the subject matter contained herein. By viewing or receiving or reading this presentation or attending any meeting where this presentation is made, you agree to be bound by the limitations, qualifications and restrictions set out below.

Certain statements in this presentation are not historical facts and may be forward-looking statements. Forward-looking statements include statements regarding the intent, belief or current expectations with respect to the Company's expectations, intentions and projections regarding its future performance including the Company's Guidance for 2023; currency exchange rate fluctuations; anticipated events or trends and other matters that are not historical facts, including with respect to the potential FDA marketing authorization, implementation of manufacturing and quality systems, commercialization of NGAL tests, and the development of future products and new indications; concerns that may arise from additional data, analysis or results obtained during clinical trials; and, the Company's ability to successfully market both new and existing products. These forward-looking statements, which may use words such as "aim", "anticipate", "believe", "intend", "estimate", "expect" and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, and uncertainties that could cause the actual results of operations, financial condition, liquidity, dividend policy and the development of the industry in which the Company's business operates to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Factors that may impact BioPorto's success are more fully discussed in the sections captioned "Risk management" in BioPorto's 2022 Annual Report and "Significant risks and uncertainties" in BioPorto's Interim Reports.

This presentation is for information purposes only and does not constitute an offer to sell or a solicitation of any offer to buy any securities issued by the Company in any jurisdiction. The information contained herein is not for distribution in the United States of America. This document does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold within the United States absent registration or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to offer or solicit an offer to buy any securities in the Company in the United States or to make a public offering of the securities in the United States. Company securities may be sold only to qualified institutional buyers (as defined in Rule 144A under the Securities Act) in reliance on Rule 144A.

Q3 2023 Highlights: FDA 510(k) Pre-market Notification Submission Accepted

- Recorded first nine-months revenue of DKK 24.4 million, +20% as compared to the same year-ago period driven by an increase in NGAL sales
- Regulatory approval pathway for NGAL moved from De Novo application to submission of 510(k) pre-market notification which has been accepted by the FDA
- Two abstracts accepted for presentation at upcoming American Society of Nephology conference in Philadelphia (Nov 1- 4)
- Total cash of DKK 69.9 million as of September 2023
- Maintain 2023 Revenue and favorably revise Adjusted EBITDA guidance mainly due to the benefits of focused cost controls/savings

KDIGO Clinical Guideline Update

- Comments submitted to KDIGO Statement of Work working group with respect to NGAL as an AKI and AKD as a damage biomarker
- Update will refresh the current AKI/AKD practice guideline last updated in 2012
- The non-profit's clinical AKI/AKD guideline update may include NGAL as a damage biomarker for the identification of AKI/AKD for the first time in the guideline's published history

The KDIGO guidelines for AKI and AKD often drive clinical decisions in many countries

Acute Kidney Injury (AKI) - An Unmet Clinical Need

- An abrupt loss of kidney function that develops rapidly over a few hours or days.
- Symptoms may include decreased urinary output, swelling due to fluid retention, nausea, fatigue, and shortness of breath. **Often painless without symptoms.**
- **Difficult to diagnose.**
- AKI **can progress** to CKD, a lifetime of dialysis, and death.



The NGAL Test™

Sources: Silver SA, Chertow GM. The Economic Consequences of Acute Kidney Injury, Nephron. 2017;137.
A Multidisciplinary and International Assessment of Acute Kidney Injury Awareness, Ipsos MORI UK Ltd., May 25, 2022.

AKI is Common and Costly

1 in 5 ADULTS[1]
& 1 in 4 CHILDREN[2]
is affected with AKI during hospitalization

Hospital Patients at Risk of AKI:[3]

- **Cardiac Surgery**
- **Mechanical Ventilation**
- **Sepsis**
- **Organ or Bone Marrow Transplant**
- **Nephrotoxic Agents/Drugs**

Increased Length of Stay
7 – 23 DAYS[4]

Increased need for Dialysis
12% OF CRITICALLY ILL ADULTS[5]

Overall Mortality Rate
21%[6]

$7,000 increase per episode[7]

$5-20 billion annual cost[7]

bioporto DIAGNOSTICS

1. Susantitaphong P. *CJASN*. 2014;9(6)
2. Kaddourah A. N Engl J Med. 2017
3. Zeng X. CJASN 2014
4. Sutherland SM, CJASN. 2013;8(10)
5. Hoste EA. Intensive Care Med. 2015
6. Mehta RL. Lancet. 2015
7. Silver SA. Nephron. 2017;137

 |

NGAL: Improving the Standard of Care



Serum Creatinine is Inadequate

2-3 days delayed[1]

43% *of patients* ***missed*** *using SCr alone*[2]

66% of AKI is misclassified[3]

70% of clinicians believe they are missing AKI[4]

1. Devarajan P. Biomark Med. 2010;4(2):265-280 2. Haase et al. J Am Coll Cardiol 2011 3. Ricci et al J Cardiothorac Vasc Anesth. 2022 4. A Multidisciplinary and International Assessment of AKI Awareness. Ipsos MORI UK Ltd May 2022

 |

Reagent-only Product Run on Standard Clinical Chemistry Instruments

High-Value Diagnostic price point

No investment in capital equipment

High margins even at today's scale

Roche

SIEMENS Healthineers

Abbott

BECKMAN COULTER

QuidelOrtho

US Market: Preparations U.S. NGAL Approval Moves Forward With Roche

- Awaiting 510(k) pre-market clearance approval in order to market NGAL test for pediatric use in the ICU
- Collaboration with our distribution partner Roche Diagnostics moves forward in preparation for approval will allow BioPorto to leverage their vast footprint
- Roche Diagnostic is an industry leader with machines that are readily available at large academic medical institutions which handle the most complicated patient procedures
- In the US, the term 'pediatric' means patients between greater or equal to 3 months and under 22 years of age.
- This beachhead will demonstrate the life and cost saving value of NGAL that will enable rapid adoption for testing the Adult population market following FDA clearance

Previously the FDA has already granted the NGAL test breakthrough designation status

US TAM Growth: Broadening Compatibility & Adult Label Expansion



1. Roche *c 501 Instrument
2. Following subsequent CLIA filing to expand compatibility with expanded Roche family of Instruments
3. Combined Emergency Room, Cardiac ByPass Surgery, Cirrhosis, Kidney Transplant, Initiation/Liberation from Dialysis, etc.
4. Pediatrics ICU Roche Instrument - $8.8M, Pediatrics ICU Open Channel non-specific Instrument - $23M, Pediatrics All Departments non-specific Instruments - $104M

Our Global Sales Effort

Multi-pronged sales approach:

- Select and train qualified distributor partners on clinical sales
- Provide expert Medical Affairs support
- Engage in Direct Marketing
- Leverage KOLs experienced in NGAL testing

~$1B

untapped market

Clinical Champions

Lab Committees & Reimbursement

Lab Validation

Electronic Health Record

Clinical Education

Clinical Workflow

No additional registration requirements to access adult and pediatric markets

Gain FDA Approval, Expand Total TAM in the U.S. Grow the Business in ROW

Our Strategic Focus

- Support FDA approval of NGAL test for Pediatrics
- Expand market opportunity in US by performing studies to expand instrument and clinical indications
- Drive NGAL sales in ROW and where CE mark is accepted

Strengthen to Scale & Execute

- Execute appropriate financing rounds
- Drive high-margin antibody sales to offset future capital requirements
- Suspend new biomarker development activities
- Ensure systems and backup data files are FDA audit-ready

Attract, Develop & Retain the Best Employees

- Proactively recruit the most qualified talent to drive success
- Motivate and incentivize employees to stay & build shareholder value

Revenue: DKKm 24.4, up 20% YTD over prior year

Annual Revenue by Product Group*



Revenue by Quarter*



* all amounts in DKKm

NGAL test sales up 50% on LTM basis

Global NGAL

↑ 50%

Growth in YTD global NGAL test sales vs. the previous last twelve months



Cash position and working capital management



- **YTD 2023 cash use from operations:** DKKm 53.4, primarily reflecting payment of clinical trial and restructuring costs
- **Restructuring charge:** DKKm 2.9 to better align resources with BioPorto's strategic priorities
- **Cash balance:** DKKm 69.9
  Includes DKKm 41.3 million net proceeds from pre-emptive rights offering

Note: Adjusted EBITDA is a non-IFRS measure. Please see BioPorto's Annual and Interim Reports for a description of this measure and a reconciliation to EBIT.

2023 Outlook

Amounts in millions of Danish Kroner and US Dollars[1]

2023 Outlook

Revenue	DKK 30-33 $4.4-4.8
Adj. EBITDA loss	DKK (56)-(59) $(8.1)-(8.6)

Actual at Sep 30, 2023

Cash[2]	DKK 70 $9.9

[1]All Financial Figures Converted from DKK to USD at a rate of 6.8812 as of September 30, 2023. [2]Unaudited.

Note: BioPorto's performance and guidance for 2023 is based on certain assumptions described in the annual and interim report(s) and continues to be subject to uncertainty due to COVID-19, including continued opening of societies and the normalization of access to hospitals, research laboratories, and regulatory bodies. Please see the Company's 2023 Annual Report and Interim Reports for further information on risks and uncertainties. Adjusted EBITDA is a non-IFRS measure. Please see BioPorto's Annual and Interim Reports for a description of this measure and a reconciliation to EBIT.

bioporto
DIAGNOSTICS

Contacts:

EU: Tim Eriksen, Managing Partner
Zenith Advisory, investor@bioporto.com
+45 4529 0000

US: Ashley Robinson, Managing Director
LifeSci Advisors, arr@lifesciadvisors.com
+1 617 430 7577

CPH: BIOPOR